antibody-therapeutics

Adagio Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory viruses.

Teneobio — independent third-party profile of a public API surface, by API Evangelist. Teneobio was a privately held, clinical-stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), for the treatment of cancer, autoimmunity, and infectious diseases.

Alchemab Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Alchemab Therapeutics is a UK-based clinical-stage biotechnology company developing next-generation antibody therapeutics for hard-to-treat diseases. Its "Adaptive Immunity" platform identifies naturally resilient individuals, such as long-term cance

Dren Bio — independent third-party profile of a public API surface, by API Evangelist. Dren Bio is a clinical-stage biopharmaceutical company based in Foster City, California, focused on the discovery and development of novel antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.

Compass Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics for the treatment of cancer. Its research is grounded in understanding the tumor microenvironment, designing candidates that optimize